Biogen Just Spent $850M to Bet Big on China. Here's Why.
Biogen just paid $100 million upfront (with up to $850M on the table) to lock down worldwide rights to an experimental immune disease drug, going deeper into China while everyone else pulls back. The deal reveals just how irresistible the math is in China's booming autoimmune market.
The Price of Going Global
Most companies consolidate their supply chains out of China right now. Biogen just wrote a $100 million check to go deeper in.
The Cambridge, Massachusetts-based biotech agreed to pay up to $850 million to acquire exclusive Greater China rights to felzartamab, an experimental antibody for immune-mediated diseases, from TJ Biopharma. The deal gives Biogen something it didn't have before: complete worldwide control of what Wall Street thinks could become a multi-billion-dollar franchise.
And investors loved it. Biogen shares jumped roughly 10% on the news.
But the deal raises a bigger question. In an era of the BIOSECURE Act, U.S.-China tensions, and political grandstanding about supply chains, why is one of America's biggest biotechs doubling down on the Chinese market?
Because the math is too good to ignore.
What Biogen Actually Bought
Let's start with the asset. Felzartamab is a CD38-directed antibody, which is a fancy way of saying it hunts down and destroys a specific type of immune cell called plasma cells. These cells are normally the good guys; they produce antibodies to fight infections. But in certain diseases, they go rogue and churn out harmful antibodies that attack the body's own tissues.
Think of plasma cells like a factory that usually makes car parts. Felzartamab shuts down the factory when it starts producing defective parts that damage the cars instead.
The drug is currently in Phase 3 trials (the final stage before seeking approval) for three kidney-related immune diseases: late antibody-mediated rejection in transplant patients, primary membranous nephropathy, and IgA nephropathy. A marketing application for multiple myeloma (a blood cancer) has already been filed in China.
Biogen structured the deal to keep risk low. The $100 million upfront payment represents roughly 2% of the company's approximately $4.7 billion cash pile. The remaining $750 million comes in the form of commercial and sales milestones, meaning Biogen only pays if the drug actually succeeds in the market. TJ Biopharma also gets mid-single-digit to low-double-digit royalties on sales in Greater China.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
In dealmaking terms, this is the equivalent of putting down a small deposit on a house with a massive upside if the neighborhood booms.
Why China, and Why Now?
China's autoimmune drug market isn't just growing. It's accelerating.
The market was worth about $4.6 billion in 2024 and is expanding at a 27.6% annual clip through 2028. By 2030, it's projected to hit $19.9 billion. That growth rate absolutely dwarfs the overall Chinese pharma market, which chugs along at a more modest 6-7% annually.
The patient population tells the story. Roughly 80 million people in China suffer from autoimmune diseases, and diagnosis rates are improving quickly as the country builds out its specialist infrastructure. Biologics (the expensive, targeted therapies like felzartamab) are expected to grow from about 42% of autoimmune drug sales in 2022 to nearly 70% by 2030.
For Biogen, there's an even more specific reason to care. The company inherited felzartamab through its $1.15 billion acquisition of Human Immunology Biosciences (HI-Bio) in 2024, but that deal excluded Greater China rights. TJ Biopharma held those separately. Without this new transaction, Biogen would have owned the drug everywhere except one of the world's fastest-growing markets for it.
That's like owning a franchise restaurant chain but not having a location in the city with the most hungry customers.
Biogen's Immunology Shopping Spree
The TJ Biopharma deal isn't a one-off. It's the latest in a deliberate, multi-year buying spree as Biogen pivots from a neuroscience company into an immunology powerhouse.
Consider the timeline. In 2024, Biogen bought HI-Bio for $1.15 billion (plus $650 million in milestones), landing felzartamab and another early-stage immune asset called izastobart. In late 2025, it signed a $50 million deal with Dayra Therapeutics to develop oral treatments for autoimmune conditions. Then in October 2025, it licensed a preclinical complement-pathway drug from Vanqua Bio for $70 million upfront (with up to $990 million in milestones).
The pattern is clear. Biogen is building an entire immunology franchise from scratch, using acquisitions and licensing deals to populate every stage of the pipeline: early, mid, and late. The company now boasts 10 Phase 3 programs, with five potential new products that have established proof-of-concept.
Why the urgency? Biogen's core multiple sclerosis business faces rising generic competition. The company needs new revenue engines, and immunology is the fastest road to get there. Analysts project consensus peak global sales for felzartamab alone at over $2.8 billion annually by 2032.
The Elephant in the Room: Geopolitics
Let's address the obvious tension. The U.S. passed the BIOSECURE Act, which restricts American companies from working with certain Chinese biotech and manufacturing firms. Political rhetoric about "decoupling" from China fills the airwaves daily. So how does Biogen justify a major China deal?
The answer is surprisingly simple: the BIOSECURE Act targets manufacturing and data-security relationships, not IP licensing. Western companies can still freely in-license Chinese drug assets as long as they don't rely on designated restricted firms for production.
And the data backs this up. Cross-border licensing deals involving Greater China companies hit a staggering approximately $137.7 billion in total value in 2025, roughly ten times the figure from 2021. Deal counts rose from 65 in 2021 to 186 in 2025. Early 2026 numbers are tracking even higher, with average deal sizes jumping 76% year-over-year.
Geopolitics is changing how deals get structured (more territory splits, alternative manufacturing clauses, beefier compliance language), but it's not slowing the pace. If anything, the quality of Chinese biotech innovation is pulling more Western buyers to the table, not fewer.
What Could Go Wrong
The bull case is compelling, but the risks are real.
Felzartamab's Phase 3 readout for antibody-mediated rejection (the TRANSCEND trial) is expected in H1 2027, with the remaining kidney disease trials reading out later. If those trials miss, Biogen takes a non-cash write-down on the $100 million upfront and the entire investment thesis weakens considerably. Clinical risk in rare autoimmune diseases is no joke; the biology is complex, patient recruitment is hard, and endpoints can be tricky to hit.
China-specific execution risk also matters. Regulatory timelines, pricing negotiations, and market access in China can surprise even experienced operators. And if U.S.-China relations deteriorate further, future legislation could theoretically tighten restrictions beyond manufacturing into licensing territory.
The Bottom Line
Biogen's $850 million bet on felzartamab in China is a calculated gamble wrapped in a disciplined deal structure. The upfront cost is modest, the milestone payments only trigger if the drug works, and the market opportunity is enormous.
More broadly, this deal tells us something important about the state of global biotech: the science doesn't care about geopolitics. When a drug has blockbuster potential and a market has 80 million patients, companies will find a way to make the deal work. The paperwork just gets more complicated.
Biogen is betting that felzartamab's Phase 3 data will justify the price tag. If it does, this deal will look like one of the smartest moves in biotech this year. If it doesn't, that $100 million becomes an expensive lesson in the difference between potential and proof.
Clinical & Regulatory
4 min read
The FDA Fired Thousands of People. Now It's Hiring 2,200 Back.
The FDA slashed 3,000 workers last year. Now it's scrambling to hire 2,200 back, but the math still doesn't add up. Here's what it means for drug approvals, biotech timelines, and whether the regulatory engine can survive the whiplash.
